Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919903 | 0.80 | MAPT (0.43) | MAPTTP53POLBCHRM5AKR1B1 | |
| SCHEMBL303191 | 0.69 | EGLN1 (0.51) | MAPTAKR1B1AKR1A1 | |
| SCHEMBL5464015 | 0.66 | BRAF (0.46) | MAPTPOLBAKR1B1AKR1A1 | |
| SCHEMBL25868654 | 0.65 | AKR1B1 (0.44) | MAPTTP53POLBAKR1B1TRAP1 | |
| SCHEMBL5239737 | 0.64 | PYCR1 (0.45) | MAPTCHRM5AKR1B1TRAP1HSP90B1 | |
| SCHEMBL1310479 | 0.62 | PYCR1 (0.50) | MAPTPOLBCHRM5AKR1B1TRAP1 | |
| SCHEMBL13172655 | 0.62 | P2RX7 (0.45) | MAPTCHRM5AKR1B1TRAP1HSP90B1 | |
| SCHEMBL15053119 | 0.62 | P2RX7 (0.40) | CHRM5AKR1B1 | |
| SCHEMBL8252272 | 0.62 | PYCR1 (0.46) | AKR1B1BMP1 | |
| SCHEMBL31136303 | 0.61 | CCR5 (0.48) | MAPTAKR1B1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2326179-A1 | PROLYL HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010025087-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | MAPT 4716/4885TP53 3250/4885POLB 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.